MX2018001074A - Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. - Google Patents
Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.Info
- Publication number
- MX2018001074A MX2018001074A MX2018001074A MX2018001074A MX2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A
- Authority
- MX
- Mexico
- Prior art keywords
- natural killer
- cell lines
- cells
- modified
- increased cytotoxicity
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 6
- 230000003013 cytotoxicity Effects 0.000 title abstract 2
- 231100000135 cytotoxicity Toxicity 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 108091008042 inhibitory receptors Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Las células NK y las líneas de células NK se modifican para aumentar la citotoxicidad, en donde las células y las composiciones de estas tienen un uso en el tratamiento del cáncer. La producción de células NK y líneas de células NK modificadas es a través de una modificación genética para eliminar la expresión de un receptor inhibidor de puntos de control y/o añadir la expresión del ligando TRAIL mutante (variante).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178899 | 2015-07-29 | ||
| GBGB1603655.0A GB201603655D0 (en) | 2016-03-02 | 2016-03-02 | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| GB201605457 | 2016-03-31 | ||
| GBGB1610164.4A GB201610164D0 (en) | 2016-06-10 | 2016-06-10 | Modified natural killer cells and natural killer cell lines having increased cytoxicity |
| PCT/EP2016/068001 WO2017017184A1 (en) | 2015-07-29 | 2016-07-28 | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001074A true MX2018001074A (es) | 2018-11-12 |
Family
ID=56683913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001074A MX2018001074A (es) | 2015-07-29 | 2016-07-28 | Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. |
| MX2020010014A MX2020010014A (es) | 2015-07-29 | 2018-01-24 | Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010014A MX2020010014A (es) | 2015-07-29 | 2018-01-24 | Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10034925B2 (es) |
| EP (6) | EP3421590B1 (es) |
| JP (3) | JP6974681B2 (es) |
| KR (1) | KR20180028530A (es) |
| CN (3) | CN116064401A (es) |
| AU (2) | AU2016300128B2 (es) |
| BR (1) | BR112018001660A2 (es) |
| CA (2) | CA2993796C (es) |
| DK (3) | DK3317401T3 (es) |
| ES (5) | ES2970269T3 (es) |
| HK (1) | HK1252582B (es) |
| MX (2) | MX2018001074A (es) |
| WO (1) | WO2017017184A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CN116064401A (zh) * | 2015-07-29 | 2023-05-05 | 昂克医疗有限公司 | 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| ES2746856T3 (es) | 2016-12-09 | 2020-03-09 | Onk Therapeutics Ltd | Células asesinas naturales manipuladas y usos de las mismas |
| IL267543B2 (en) * | 2017-01-06 | 2024-07-01 | Immunitybio Inc | Adapted NK-92 cells and their compositions for use in the treatment of cancer and methods of their preparation |
| AU2018219895B2 (en) | 2017-02-09 | 2024-07-25 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| DE102017002645A1 (de) * | 2017-03-17 | 2018-09-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen |
| CA3069557A1 (en) | 2017-07-21 | 2019-01-24 | Cellectis | Engineered immune cells resistant to tumor microoenvironment |
| WO2019016360A1 (en) * | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
| EP3714040A1 (en) | 2017-11-24 | 2020-09-30 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| AU2019271366A1 (en) * | 2018-05-16 | 2021-01-14 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| US20210230542A1 (en) * | 2018-06-06 | 2021-07-29 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for cell enrichment |
| CN108743595B (zh) * | 2018-06-08 | 2020-11-27 | 厦门诺康得生物科技有限公司 | 一种nk细胞免疫检查点抑制剂及其制备方法 |
| BR112021016046A2 (pt) * | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| CN109908155A (zh) * | 2019-03-11 | 2019-06-21 | 上海中医药大学 | 丹参酮ⅱa的药物用途 |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| CA3134223A1 (en) | 2019-03-21 | 2020-09-24 | Onk Therapeutics Limited | Modified immune effector cells with increased resistance to cell death |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| RU2731293C1 (ru) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний |
| EP3789485A1 (en) * | 2019-09-06 | 2021-03-10 | ONK Therapeutics Limited | Cellular therapies for cancer |
| CN115103910A (zh) | 2019-10-03 | 2022-09-23 | 工匠开发实验室公司 | 具有工程化的双引导核酸的crispr*** |
| CN111849896B (zh) * | 2020-07-31 | 2022-07-01 | 广东昭泰体内生物医药科技有限公司 | 一种car-nk细胞培养基及其应用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022256448A2 (en) | 2021-06-01 | 2022-12-08 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| EP4370676A2 (en) | 2021-06-18 | 2024-05-22 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| EP4355860A1 (en) | 2021-06-18 | 2024-04-24 | ONK Therapeutics Limited | Double knockout natural killer cells |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| WO2023167882A1 (en) | 2022-03-01 | 2023-09-07 | Artisan Development Labs, Inc. | Composition and methods for transgene insertion |
| CN114796483B (zh) * | 2022-06-28 | 2022-11-08 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| WO2024100203A1 (en) | 2022-11-10 | 2024-05-16 | Onk Therapeutics Limited | Combined therapies using immunomodulating drugs |
| CN116590237B (zh) * | 2023-05-29 | 2023-10-31 | 上海贝斯昂科生物科技有限公司 | 一种遗传修饰的自然杀伤细胞及其制备和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413237C (en) | 2000-06-30 | 2013-09-10 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane for new functions |
| CA2388441A1 (en) | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
| WO2006004518A1 (en) * | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| EP2112162B1 (en) * | 2004-07-10 | 2015-01-14 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| EP1621550A1 (en) | 2004-07-29 | 2006-02-01 | Dompé S.P.A. | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| GB0724532D0 (en) * | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP2595637B1 (en) | 2010-07-22 | 2017-11-01 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
| ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| RU2015140941A (ru) * | 2013-02-27 | 2017-03-30 | Те Брод Инститьют, Инк. | Экспрессия генов, влияющих на баланс т-клеток, их композиции и способы применения |
| EP3026292B1 (en) | 2013-07-25 | 2019-11-27 | Bridgestone Corporation | Vibration prevention device |
| AU2014337385B2 (en) * | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Chimeric antigen receptor T cell switches and uses thereof |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| IL307423A (en) | 2014-04-07 | 2023-12-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
| JP2017513485A (ja) | 2014-04-18 | 2017-06-01 | エディタス・メディシン，インコーポレイテッド | がん免疫療法のためのｃｒｉｓｐｒ−ｃａｓ関連方法、組成物および構成要素 |
| BR112017005390A2 (pt) * | 2014-09-17 | 2017-12-12 | Novartis Ag | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva |
| WO2016160721A1 (en) | 2015-03-27 | 2016-10-06 | President And Fellows Of Harvard College | Modified t cells and methods of making and using the same |
| EP3317399B1 (en) * | 2015-06-30 | 2024-06-26 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| AR105433A1 (es) * | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
| CN116064401A (zh) * | 2015-07-29 | 2023-05-05 | 昂克医疗有限公司 | 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 |
-
2016
- 2016-07-28 CN CN202211000656.4A patent/CN116064401A/zh active Pending
- 2016-07-28 CN CN202210987123.3A patent/CN116064400A/zh active Pending
- 2016-07-28 CN CN201680049392.8A patent/CN108026512B/zh active Active
- 2016-07-28 EP EP18187137.7A patent/EP3421590B1/en active Active
- 2016-07-28 MX MX2018001074A patent/MX2018001074A/es unknown
- 2016-07-28 ES ES20213303T patent/ES2970269T3/es active Active
- 2016-07-28 JP JP2018524548A patent/JP6974681B2/ja active Active
- 2016-07-28 EP EP21152246.1A patent/EP3878951A1/en not_active Withdrawn
- 2016-07-28 BR BR112018001660-8A patent/BR112018001660A2/pt active Search and Examination
- 2016-07-28 KR KR1020187005673A patent/KR20180028530A/ko not_active Application Discontinuation
- 2016-07-28 EP EP20213303.9A patent/EP3971284B1/en active Active
- 2016-07-28 CA CA2993796A patent/CA2993796C/en active Active
- 2016-07-28 DK DK16750677.3T patent/DK3317401T3/da active
- 2016-07-28 ES ES21152473T patent/ES2939084T3/es active Active
- 2016-07-28 ES ES16750677T patent/ES2701338T3/es active Active
- 2016-07-28 EP EP21152473.1A patent/EP3828266B1/en active Active
- 2016-07-28 DK DK18194107.1T patent/DK3434762T3/da active
- 2016-07-28 EP EP18194107.1A patent/EP3434762B1/en active Active
- 2016-07-28 ES ES18194107T patent/ES2876938T3/es active Active
- 2016-07-28 WO PCT/EP2016/068001 patent/WO2017017184A1/en active Application Filing
- 2016-07-28 DK DK18187137.7T patent/DK3421590T3/da active
- 2016-07-28 ES ES18187137T patent/ES2890859T3/es active Active
- 2016-07-28 AU AU2016300128A patent/AU2016300128B2/en active Active
- 2016-07-28 CA CA3156128A patent/CA3156128A1/en active Pending
- 2016-07-28 EP EP16750677.3A patent/EP3317401B1/en active Active
-
2017
- 2017-01-12 US US15/405,163 patent/US10034925B2/en active Active
-
2018
- 2018-01-24 MX MX2020010014A patent/MX2020010014A/es unknown
- 2018-07-11 US US16/032,626 patent/US10960064B2/en active Active
- 2018-09-17 HK HK18111896.2A patent/HK1252582B/zh unknown
-
2020
- 2020-11-30 US US17/107,696 patent/US20210138051A1/en active Pending
-
2021
- 2021-07-06 JP JP2021112020A patent/JP7359346B2/ja active Active
- 2021-07-06 JP JP2021112019A patent/JP2021178824A/ja active Pending
-
2022
- 2022-05-18 AU AU2022203339A patent/AU2022203339A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010014A (es) | Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. | |
| MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| PH12017501757A1 (en) | A novel paenibacillus strain, antifungal compounds, and methods for their use | |
| MX2018010924A (es) | Células efectoras inmunitarias con edición genómica. | |
| MX2018015656A (es) | Compuestos heterociclicos como antibacterianos. | |
| MX2017002271A (es) | Composiciones y metodos para el tratamiento de trastornos neurologicos. | |
| MY191210A (en) | Novel promoter and uses thereof | |
| AU366476S (en) | Bottle | |
| MX2018002999A (es) | Composiciones de inoculante estables y metodos para producir las mismas. | |
| EP3598980A3 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| MX2014001218A (es) | Tratamiento de cancer de mama. | |
| MX2024001617A (es) | Composiciones biofarmaceuticas. | |
| PH12019502036A1 (en) | Peptides and methods for the treatment of diabetes | |
| MX2017008414A (es) | Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas. | |
| PH12020550964A1 (en) | Heavy chain antibodies binding to cd22 | |
| MX2017003903A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
| WO2015106043A3 (en) | Novel synthetic biology-based adcc technology | |
| MX2019000677A (es) | Células miméticas de células b. | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| MX2022005790A (es) | Elementos reguladores de planta y metodos para usarlos. | |
| MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| MX2016011416A (es) | Composiciones de glicoproteinas sialiladas y usos de estas. | |
| MX2018011512A (es) | Uso de insulina para promover el vaciamiento gástrico. | |
| PH12016501780A1 (en) | Rna production in higher plants |